Unlock instant, AI-driven research and patent intelligence for your innovation.

Immunostimulatory nucleic acids

An immune stimulation and nucleic acid technology, applied in biocides, organic chemistry, animal husbandry, etc., can solve the problem of weak activation ability

Inactive Publication Date: 2005-10-26
COLEY PHARMA GRP INC +1
View PDF24 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

One class activates B cells but is less able to induce IFN-α and NK cell activation; this class is called class B

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunostimulatory nucleic acids
  • Immunostimulatory nucleic acids
  • Immunostimulatory nucleic acids

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0463] The levels of interferon-α (IFN-α), IFN-γ, IL-10, IL-6, and TNF-α secreted by human PBMC after exposure to the CpG oligonucleotides described herein are shown in the accompanying drawings 1-5. The detection oligonucleotides are indicated by ▲ in the figure. Oligonucleotides serving as positive control oligonucleotides are indicated by -. Detection oligonucleotides shown in Figures 1A, 2A, 3A, 4A, and 5A include SEQ ID NO:322, SEQ ID NO:323, and SEQ ID NO:324. Detection oligonucleotides shown in Figures 1B, 2B, 3B, 4B, and 5B include SEQ ID NO:325, SEQ ID NO:326, SEQ ID NO:327, and SEQ ID NO:328. The concentration of oligonucleotide used to generate each data point is indicated along the X-axis (μΜ). Below the graphs are listed the levels of cytokines secreted by cells treated with a negative control (medium), and in some cases LPS was also used in each experiment.

[0464] As demonstrated in Figures 1-5, the oligonucleotides tested in the assay were able to elicit s...

Embodiment 2

[0466] The level of CD69 expression (MFI) of NK cells in response to treatment with the detection oligonucleotide relative to the control oligonucleotide was examined. CD69 expression is a hallmark of T cell and NK cell activation. Cells exposed to detection oligonucleotides are indicated by ▲ in FIG. 6 . Oligonucleotides serving as positive control oligonucleotides are indicated by -. Detection oligonucleotides shown in Figure 6A include SEQ ID NO:322, SEQ ID NO:323, and SEQ ID NO:324. Detection oligonucleotides shown in Figure 6B include SEQ ID NO:325, SEQ ID NO:326, SEQ ID NO:327, and SEQ ID NO:328. The positive control oligonucleotide used in these studies was SEQ ID NO:329. The levels of CD69 expression in T cells and NK cells treated with negative control (medium) and LPS for each experiment are listed below the graph.

[0467] As demonstrated in Figure 6, the oligonucleotides tested in the assay were able to induce the expression of CD69 at levels comparable to or h...

Embodiment 3

[0469] The levels of interferon-α (IFN-α) and IL-10 secreted by human PBMC following exposure of these cells to the CpG oligonucleotides described herein are shown in Figures 7-12 and 17 . The detected nucleotides are indicated by ■ in the figure. The oligonucleotide of SEQ ID NO: 242 as the positive control oligonucleotide is indicated by ●. The oligonucleotide of SEQ ID NO: 330 as a negative control oligonucleotide is indicated by ♦. Figure 7A and 7B The detection oligonucleotide shown is SEQ ID NO:313. Figure 8A and Figure 8BThe detection oligonucleotide shown is SEQ ID NO:314. Figure 9A and 9B The detection oligonucleotide shown is SEQ ID NO:319. Figure 10A and Figure 10B The detection oligonucleotide shown is SEQ ID NO:316. Figure 11A and 11B The detection oligonucleotide shown is SEQ ID NO:317. Figure 12A and 12B The detection oligonucleotide shown is SEQ ID NO:320. Figure 17A and 17B The detection oligonucleotide shown is SEQ ID NO:321. The concen...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
sizeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a class of flexible or semi-flexible CpG immunostimulatory oligonucleotides useful for stimulating immune responses.

Description

field of invention [0001] The present invention relates to immunostimulatory nucleic acids, as well as immunostimulatory oligonucleotides having reduced renal inflammatory responses, compositions thereof, and methods of using said immunostimulatory nucleic acids. Background of the invention [0002] Bacterial DNA has an immunostimulatory effect that activates B cells and natural killer cells, but vertebrate DNA does not have this effect (tokunaga, T., et al., 1988. Jpn. J. Cancer Res. 79: 682-686; Tokunaga, T., et al., 1984, JNCI 72:955-962; Messina, J.P., et al., 1991, J. Immunol.147:1759-1764; and Krieg, 1998, In: Applied Oligonucleotide Technology, C.A. Review by Stein and A.M. Krieg, (Eds), John Wiley and Sons, Inc., New York, NY, pp. 431-448). These immunostimulatory effects of bacterial DNA are now recognized to be due to the ubiquity of unmethylated CpG dinucleotides in specific base sequences (CpG motifs) in bacterial DNA but methylated in vertebrate DNA and the nu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A01N43/04A61K31/70C07H19/00C07H21/00C07H21/02C07H21/04
Inventor 阿瑟·M·克里格尤利里克·塞缪洛特兹乔格·沃尔默欧金·尤尔曼玛丽恩·朱克格雷森·利甫福德罗伯特·兰金
Owner COLEY PHARMA GRP INC